Board and Leadership Team
Dr Peter Fields
Peter has a PhD in Chemical Engineering from the University of Cambridge and spent 15 years with ICI plc working in a variety of senior management roles in the areas of research and development, biological products, petrochemicals and chemical distribution. In 1999, Peter led the management buy-out of Chance and Hunt, subsequently merging with Azelis SA to form a leading European specialty chemical distributor with a turnover in excess of €1 billion. Having left Azelis in 2009, Peter has worked as a Chairman/ entrepreneur /investor in a number of start-up companies in the chemicals and consumer sectors and joined Aqdot as Chairman in September 2013. He brings a breadth of experience of global specialty chemicals markets and an in-depth knowledge of how to transform small/start-up companies into successful businesses.
Chief Executive Officer
Tim joined Aqdot as CEO in November 2014. Prior to joining he co-founded Solent Pharma Ltd, a privately held speciality pharmaceutical company and has undertaken consulting projects supporting a variety of businesses as they develop growth and funding strategies. Previously Tim was CEO of IS Pharma plc, which he led through turnaround to become a substantial, profitable speciality business before its successful merger with Sinclair Pharma in 2011. He served as a non-executive director of the enlarged group, Sinclair IS Pharma, until 2012. Tim has previously held senior domestic and international commercial roles with Élan, SmithKline Beecham and Pfizer. Tim has successfully developed, licensed and grown brands and businesses at all stages of their lifecycle. He is a Fellow of the Chartered Institute of Marketing, a Fellow of the Institute of Directors and a Chartered Director.
Dr Roger Coulston
Chief Scientific Officer
Roger is the Chief Scientific Officer, and co-founder, of Aqdot. Prior to founding Aqdot, Dr Coulston was a Post-Doctoral Research Associate in the Scherman Research Group in the Department of Chemistry, University of Cambridge. His research interests include dynamic supramolecular assemblies through molecular recognition processes. He also co-invented the Aqdot core technology and was awarded the European Research Council Proof-of-Concept Grant in 2012 to fund the technology and market validation of the supramolecular capsules. Roger has a Bachelor of Medical Science and a PhD in physical organic chemistry from the Australian National University. Roger is also a trained food technologist (dairy) with experience in large scale food processing.
Dr Gordon Jamieson
Head of Commercial Operations
Gordon joined Aqdot in July 2016. He has extensive experience in international businesses, successfully leading teams that have developed and marketed new technologies in life-science and chemical sectors, and frequently working in international collaborations with companies ranging from start-ups to industry leaders. His career started at ICI (now AstraZeneca and Syngenta) where he successfully commercialised new chemistries. Since then he has worked in chemical, food, agriculture and pharmaceutical sectors, exploiting innovative science and business opportunities. He has a broad scientific background with a PhD in genetics from Nottingham University.
Dr Sarah Shepley
Head of Business Development
Sarah, who joined Aqdot in 2017, has extensive experience in the petrochemicals, renewables and materials sectors, including senior assignments in R&D, Manufacturing, IPR and Technology Licensing with ICI and DuPont. Prior to joining Aqdot, Sarah was Director of Corporate Partnerships at Imperial College London, and Commercial Director of Plaxica Ltd, delivering commercialisation of early-stage technologies via partnerships with a wide range of companies around the world. Sarah earned her BSc and PhD in Chemistry Imperial College, London and is a Fellow of the Royal Society of Chemistry.
Dr Jing Zhang
Jing is the Marketing Director and cofounder of Aqdot. While working to complete her PhD on microfluidic droplets in the Department of Chemistry, University of Cambridge, she co-invented the core technology in collaboration with Dr Roger Coulston and prepared the manuscript for publication of the research findings in Science. During her time in Cambridge, she was also actively involved in the entrepreneurial community, leading the Cambridge University Entrepreneurs, a 2000-member not-for-profit organisation aimed at promoting entrepreneurship among students. Prior to moving to Cambridge, Jing was awarded a Bachelor of Philosophy with first class honours and a University Medal from the Australian National University.
Dr John Hamlin
Dr John Hamlin serves as independent non-executive director at Aqdot. He was previously part-time CEO from the company’s formation until November 2014. He remains actively involved as an advisor. Before joining Aqdot, John was the CEO at Plaxica, a technology and licensing company focused on the production of platform chemicals and polymers from renewable resources. John also works closely with the Venture Team at Touchstone Innovations where he is Entrepreneur in Residence. John brings more than 25 years industrial experience at BP, holding several senior international business and technology positions. Most of his career has been in the chemicals and polymers sector and he brings an experience of the main value chain operators, manufacturing technologies and the various markets for speciality and high volume plastics.
Kelsey Lynn Skinner
Kelsey is the Tech Ventures Director of Touchstone Innovations. Prior to joining Touchstone, she was a Partner at Firelake Capital, a Palo Alto VC firm specialising in energy and materials science investments. Kelsey focused on commercialization of new materials technologies and business models; she held board director or observer seats with Zeachem, EnerG2, EOS Climate and Simbol Materials. An engineer by training, Kelsey has worked in energy technology since 2003, including roles with Google’s green energy strategy group and Stanford’s Global Climate and Energy Project (GCEP). Kelsey has a BSc and MSc from Stanford University, and later studied for an MBA from Stanford’s Graduate School of Business.
Scientific Advisory Board
Professor Chris Abell
Cofounder and Scientific Advisor
Chris is a Professor of Biological Chemistry in the Department of Chemistry at the University of Cambridge where his research applies inter-disciplinary approaches to solving problems in biological chemistry. His research is primarily focused in two areas: developing picodroplets as an experimental platform, and pioneering new approaches to drug discovery. Prof. Abell has been involved in the creation of several companies. He was a co-Founder of Astex Therapeutics, a Cambridge spin-out company working on fragment-based drug discovery. He also co-Founded Akubio, a company developing novel acoustic biosensors, is a founding scientist of Ionscope, a company developing a novel, scanning ion probe microscope, and is the cofounder and director of Sphere Fluidics, a life sciences company which has developed unique products for use in single cell analysis and characterisation. Professor Abell is a Fellow of the UK Academy of Medical Sciences.
Professor Oren Scherman
Cofounder and Scientific Advisor
Oren is the Director of the Melville Laboratory for Polymer Synthesis at the Department of Chemistry, University of Cambridge. His research group are interested in studying supramolecular polymers, hydrogels and composite materials and their dynamics of assembly in an aqueous environment. Piror to moving to Cambridge, Oren worked on supramolecular polymers, at the Eindhoven University of Technology with Professors E. W. (Bert) Meijer and Rint P. Sijbesma after he finished his PhD under the supervision of Professor Robert H. Grubbs at the California Institute of Technology (Caltech) in Pasadena, California in 2004.